Victoria Socha

DocwireNews

Allografts from living <a href="https://www.docwirenews.com/latest-nephrology-news/hyperkalemia-in-solid-organ-transplant-recipients/">kidney donors</a> may carry subclinical pathological abnormalities to the recipient, increasing the risk for adverse clinical outcomes. Diminished number of nephrons is one mechanism associated with hypertension. Recipients of allografts from donors with hypertension may have insufficient number of nephrons, leading to adverse outcomes associated with hyperfiltration injury.Researchers at Johns Hopkins, Baltimore, Maryland, led by F. Al Ammary, conducted an analysis to examine change in estimated glomerular filtration rate (eGFR) over time and survival in recipients of allografts from donors with versus without hypertension, stratified by donor age. Results were reported during a virtual <a href="https://atcmeetingabstracts.com/abstract/long-term-outcomes-in-recipients-of-allografts-from-living-kidney-donors-with-hypertension/">poster</a> session at the American Transplant Congress 2020 in a poster titled Long-Term Outcomes in Recipients of Allografts from Living Kidney Donors with Hypertension.The researchers utilized a national cohort of adult living-donor kidney transplantation recipients from January 1, 2005, to June 30, 2017, to identify 49,990 recipients from donors &le;50 years of age (younger), including 597 whose donors had hypertension and 21,130 recipients from donors &ge;50 years of age (older), including 1441 whose donors had hypertension. Mixed models with random intercepts and random slopes and Cox regressions models adjusting for recipient, donor, and transplant characteristics were used in the analyses.Median follow-up was 5.4 years. In the cohort of recipients from younger donors with versus without hypertension, the annual decline in eGFR was &ndash;1.10 mL/min/1.73 m2 versus &ndash;0.50 mL/min/1.73 m2, respectively (P&lt;.01). The 12-year all-cause graft survival was 50.3% versus 56.0%, respectively (graft failure hazard ratio [HR] 1.21; 95% confidence interval [CI], 1.03-1.43; P=.02).Among recipients from older donors with versus without hypertension, the annual decline in eGFR was &ndash;0.68 mL/min/1.73 m2 versus &ndash;0.64 mL/min/1.73 m2, respectively (P=.7). The 12-year graft survival was 50.7% versus 50.0%, respectively (graft failure HR, 1.04; 95% CI, 0.93-1.17; P=.5).&ldquo;Hypertension in younger, but not in older, donors was associated with worse recipient outcomes,&rdquo; the researchers said.Source: Ammary FAI, Yu S, Muzaale A. et al. Long-Term Outcomes in Recipients of Allografts from Living Kidney Doors with Hypertension. Abstract of a poster presented at the virtual American Transplant Congress 2020 (Abstract C-081), May 30, 2020.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Outcomes among Recipients of Kidney Allografts from Donors with Hypertension

American Transplant Congress 2020

Allografts from living kidney donors may carry subclinical pathological abnormalities to the recipient, increasing the risk for adverse clinical outcomes. Diminished number of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe